Merck prepares strategic options for its Consumer Health Business

Amy Schofield 05 September 2017

Merck has announced that it is preparing strategic options for its Consumer Health business, including a potential full or partial sale of the business as well as strategic partnerships. 

The Consumer Health business features a number of leading products in over-the-counter categories. The business focuses on consumer-centric solutions driven by global megatrends and achieved net sales of €860 million in 2016. Consumer Health's portfolio includes brands and products such as Bion®, Femibion®, Nasivin®, Neurobion®, and Seven Seas®.

Any possible proceeds from a potential transaction would be used to deliver on the company’s overall financial targets.

Stefan Oschmann, Chairman of the Executive Board and CEO of Merck, said: “We have continued to transform Merck over the last years into a leading science and technology company. Thereby we regularly review our portfolio in the context of our innovation driven strategy. Healthcare largely focuses on its Biopharma pipeline."

Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare, said: “We have maintained a solid position in attractive markets, and demonstrated a pattern of profitable growth. We expect increasing internal constraints to fund the business to reach the required scale. Fully anticipating this, we are preparing strategic options."


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.